收藏切换
Consideration and suggestion on clinical drug switching of biosimilars in China
收藏切换
Zi-yue XU1, Sheng HAN2, Xiao-dong GUAN1, 2, Lu-wen SHI1, 2
Chinese Journal of New Drugs | 2021, 30(17) : 1554 - 1558
Less
收藏切换
Chinese Journal of New Drugs | 2021, 30(17): 1554-1558
Consideration and suggestion on clinical drug switching of biosimilars in China
Full
Zi-yue XU1, Sheng HAN2, Xiao-dong GUAN1, 2, Lu-wen SHI1, 2
Affiliations
  • 1School of Pharmaceutical Sciences, Peking University, Beijing 100191, China
  • 2International Research Center for Medicinal Administration, Peking University, Beijing 100191, China
Published: 2021-09-15
Outline
收藏切换

The aim of this article is to make some suggestions for the regulations on interchangeability and clinical drug switching of biosimilar in China. Literature and relevant policies were reviewed. The development status of biosimilars in China was summarized, the regulatory experiences on the interchangeability of biosimilars in the United State and European Union were combed, and research findings on clinical drug switching were analyzed as well. Biosimilars have developed rapidly in China, but the related regulatory system has not been completely established. The United States and European Union have already initially established the management of biosimilar interchangeability, while the practical experience and clinical evidence are limited, and expert consensus has not been reached. There are still potential risks and concerns on switching from an originator biologic to a biosimilar or from one biosimilar to another. Drug regulatory authority should pay more attention to drug safety, clinical data information transparency, and technical guidelines on interchangeability, drug traceability, and incentive system.

biosimilar  /  reference product  /  clinical drug switching  /  interchangeability
徐子悦, 韩晟, 管晓东, 史录文. 生物类似药临床用药互换的思考与建议. 中国新药杂志, 2021 , 30 (17) : 1554 -1558 .
Zi-yue XU, Sheng HAN, Xiao-dong GUAN, Lu-wen SHI. Consideration and suggestion on clinical drug switching of biosimilars in China[J]. Chinese Journal of New Drugs, 2021 , 30 (17) : 1554 -1558 .
Year 2021 volume 30 Issue 17
27
10
Cite this Article
BibTeX
Article Info
  • Online Date:2026-10-28
  • Published:2021-09-15
Article Data
Affiliations
History
  • Accepted:2021-02-01
Affiliations
    1School of Pharmaceutical Sciences, Peking University, Beijing 100191, China
    2International Research Center for Medicinal Administration, Peking University, Beijing 100191, China
References
Share
https://castjournals.cast.org.cn/joweb/zgxyzz/EN/
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT